Truqap 160 mg (Capivasertib Tablet) 160 MG

TRUQAP 160 MG (capivasertib) is an oral tablet used alongside endocrine therapy for certain breast cancers. This prescription medication targets hormone receptor-positive conditions. Store at room temperature and keep out of reach of children. Always follow your healthcare provider’s guidance.

Strength

160 MG

Pack Size

64s

Storage

Ambient

Manufacturer / TM Owner

ASTRA ZENECA PHARM

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

TRUQAP 160 MG is prescribed for adults with hormone receptor-positive, HER2-negative breast cancer in combination with fulvestrant. It is used after prior endocrine therapy has been tried. The tablet form supports targeted treatment when combined with other therapies. Patients should discuss suitability with their doctor.

Side Effects

TRUQAP 160 MG works by influencing cellular pathways involved in cancer growth. Common effects may include gastrointestinal changes and fatigue. Some users report mild nausea or digestive discomfort. These effects vary and should be monitored by a healthcare professional.

Precautions & Warnings

Keep TRUQAP 160 MG in its original packaging at room temperature. Avoid exposure to moisture and direct sunlight. Do not use if the seal is broken or the product appears damaged. Inform your doctor about all medications and health conditions before starting this treatment.

Avoid Interactions

TRUQAP 160 MG may interact with strong CYP3A inhibitors or inducers, altering its effectiveness. Grapefruit products can also affect metabolism. Discuss all prescription, over-the-counter, and herbal products with your healthcare provider. Alcohol use should be minimized during treatment.

Frequently Asked Questions

TRUQAP 160 MG is used to treat certain types of hormone receptor-positive breast cancer in adults when combined with fulvestrant.

Store TRUQAP 160 MG at room temperature in a dry place, away from heat and moisture.

Always consult your doctor before combining TRUQAP 160 MG with other drugs, including over-the-counter and herbal products.

Common effects may include nausea, fatigue, or digestive discomfort. Report any persistent issues to your healthcare provider.

TRUQAP 160 MG is a targeted therapy, not a traditional chemotherapy agent.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.